WHO ICTRP trial
Lithium for mild-to-moderate Alzheimer's disease: A randomized double-blind…
JPRN-UMIN000020128 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000020128 |
|---|---|
| Public title | Lithium for mild-to-moderate Alzheimer's disease: A randomized double-blind, placebo-controlled study |
| Scientific title | Lithium for mild-to-moderate Alzheimer's disease: A randomized double-blind, placebo-controlled study - Lithium for mild-to-moderate Alzheimer's disease: A randomized double-blind, placebo-controlled study |
| Primary sponsor | Department of Psychiatry, Fujita Health University School of Medicine |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Not selected |
| Countries | Japan |
| Conditions | Alzheimer's disease |
| Interventions | Lithium, 300 micrograms/day, once daily, 52 weeks Placebo, once daily, 52 weeks |
| Registration date | Nov 12, 2015 |
| Target size | 100 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: